Recursion Pharmaceuticals
RXRX
336 hedge funds and large institutions have $1.63B invested in Recursion Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 138 increasing their positions, 71 reducing their positions, and 43 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 71
49% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 43
30% more call options, than puts
Call options by funds: $28.3M | Put options by funds: $21.7M
6% more funds holding
Funds holding: 316 → 336 (+20)
1.55% less ownership
Funds ownership: 79.42% → 77.87% (-1.5%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
21% less capital invested
Capital invested by funds: $2.06B → $1.63B (-$433M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$30.2M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$18.7M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$18M |
| 4 |
Morgan Stanley
New York
|
+$15.7M |
| 5 |
KA
Kinnevik AB
Stockholm,
Sweden
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$52.2M |
| 2 |
DM
Deerfield Management
New York
|
-$15.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.6M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$6.63M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$4.54M |
RXRX Hedge Fund Activity: Q1 2025 in Review
336 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q1 2025, worth a combined $1.63B — down 21% from $2.06B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new RXRX positions and 43 closed out — a net gain of 21 holders — while 138 added to existing stakes and 71 trimmed.
The largest buyer was UBS AM, adding an estimated $30.2M. The largest seller was RA Capital Management, exiting entirely with an estimated $52.2M sold.
- 336 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q1 2025, up from 316 in Q4 2024.
- Funds reported $1.63B of Recursion Pharmaceuticals stock for Q1 2025, down 21% quarter-over-quarter.
- 64 funds opened new Recursion Pharmaceuticals positions in Q1 2025 and 43 closed out, a net change of +21 holders.
- The largest Recursion Pharmaceuticals buyer in Q1 2025 was UBS AM, an estimated $30.2M added.
- The largest Recursion Pharmaceuticals seller in Q1 2025 was RA Capital Management, an estimated $52.2M sold.
Based on aggregated 13F filings for Q1 2025.